MUNICH/TUEBINGEN, GERMANY, Immatics Biotechnologies has closed a 34 million euro Series D financing round to continue development of cancer vaccines.
A German company working to develop cancer vaccines has closed a 34 million euro Series D financing round.
Immatics Biopharma, based in Munich and Tuebingen, will use the funds to conclude development of its lead vaccine IMA901, which is designed to fight peptides that are highly overexpressed in patients suffering from renal cell carcinoma. The company will receive the first 12 million euro tranch of this funding round immediately.
This Series D round was supported by existing investors, including dievini Hopp Biotech Holding, Wellington Partners, MIG-advised funds, and AT Impf GmbH.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about